Antiretroviral drug not effective for viral suppression

Researchers conducted a randomized double-blind study of the effectiveness of an HIV vaccine and has found it to be ineffective in suppressing the virus. Antiretroviral therapy (ART) drugs allow people infected with the virus to live an almost normal existence.
Injecting patients first with a HIV multi-antigen and a DNA plasmid encoding human interleukin proteins and then following up with a booster containing a viral vector. The idea behind this approach is to nudge the immune system into learning how to combat the virus so that ART drugs are no longer needed.

The research team conducted a study designed to test the effectiveness of the vaccine. The study consisted of enlisting the assistance of early-stage patients with HIV infections who were already being treated with ARTs and assigning them to two groups-some of the patients got the vaccine while others got a placebo. Injections took place at 0, 4, 12, 24, 36 and 48 weeks. ART drug administration was halted for all of the volunteers starting at week 56 and lasting until week 72.

All of the volunteers were tested regularly throughout the study for viral loads, a measure of how well the body, along with ARTs and the vaccine, was working to suppress the virus. The researchers report that they found no measurable increase in effectiveness in any of the volunteers who were given the vaccine. Some of the volunteers who had received the placebo had lower than normal viral loads for a short time. This showed that if the study had not been conducted with placebos, the results would have showed that the vaccine had worked to a limited extent.
           haleplushearty.blogspot.com

Heplisav-B for prevention of Hepatitis B

U.S. Food and Drug Administration (FDA) has approved Heplisav-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for prevention of infection caused by all known subtypes of hepatitis B virus in adults. Hepatitis B is an extremely infectious and potentially deadly virus.

 There is no cure for hepatitis B, and infections are on the rise. Hepatitis B can be prevented through effective vaccination. Current hepatitis B vaccines require three shots over a six-month period, however, almost half of adults fail to complete the series within one year.

Prevention of hepatitis B in adults through vaccination is more important than ever given the increase in the rate of infections. A two-dose schedule with higher rates of protection, along with other strategies, may help us move closer to the goal of eliminating hepatitis B.

Hepatitis B is a viral disease of the liver that can become chronic and lead to cirrhosis, liver cancer and death. The hepatitis B virus is 50 to 100 times more infectious than HIV, transmission is on the rise. There is no cure for hepatitis B, but effective vaccination can prevent the disease. In adults, hepatitis B is spread through contact with infected blood and through unprotected sex with an infected person.

 The CDC recommends vaccination for those at high risk for infection due to their jobs, lifestyle, living situations and travel to certain areas. People with diabetes are particularly vulnerable to infection, the CDC recommends vaccination for adults age 19 to 59 with diabetes as soon as possible after their diagnosis, and for people age 60 and older with diabetes.

Heplisav-B is an adult hepatitis B vaccine that combines hepatitis B surface antigen with Dynavax's proprietary Toll-like Receptor (TLR) 9 agonist to enhance the immune response. Dynavax has worldwide commercial rights to Heplisav-B. Heplisav-B is indicated for active immunization against infection caused by all known subtypes of hepatitis B virus. Heplisav-B is approved for use in adults 18 years of age and older.

Do not administer Heplisav-B to individuals with a history of severe allergic reaction like anaphylaxis after a previous dose of any hepatitis B vaccine or to any component of Heplisav-B, including yeast. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of Heplisav-B.

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to Heplisav-B. Hepatitis B has a long incubation period. Heplisav-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration. The most common patient reported adverse reactions reported within 7 days of vaccination were injection site pain, fatigue and headache.
      haleplushearty.blogspot.com

Cyltezo for chronic inflammatory diseases

Cyltezo is for the treatment of multiple chronic inflammatory diseases, including: moderate to severe active rheumatoid arthritis, moderate to severe polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, moderate to severe active adult Crohn’s disease,
moderate to severe active ulcerative colitis and moderate to severe plaque psoriasis

Patients treated with adalimumab products, including Cyltezo, are at increased risk for developing serious infections that may lead to hospitalization or death.

Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease.

Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.

Do not start Cyltezo during an active infection, including localized infections.
Patients older than 65 years, patients with co-morbid conditions and patients taking concomitant immunosuppressants may be at greater risk of infection.

Cyltezo for patients with these disorders; discontinuation of Cyltezo should be considered if any of these disorders develop.
Hematological Reactions
Congestive Heart Failure
Autoimmunity
Patients on Cyltezo should not receive live vaccines.
          haleplushearty.blogspot.com

Nanoparticle vaccine can kill different types of cancer

Researchers at UT Medical Center has developed nanoparticle vaccine Immunotherapy that can kill different types of cancer.

Nanoparticle vaccines provide minuscule particles that activate the immune system to mount an immune response.

Vaccines normally use immune cells to get tumor antigens where it is located and move to the lymphoid organs for T cell activation.

Nanoparticle vaccines can go directly to the lymph nodes to activate the particular tumor immune responses.

Researchers tested many tumor models in mice like: colorectal cancer, melanoma, cancers of the cervix, head, neck and anogenital region.

Nanoparticle hinders tumor growth and increase the lifestyle of mice, this will be a suitable vaccine for patients with multiple cancer.